ISELIN, N.J., June 11, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the commercialization and development of ONS-5010/LYTENAVA™ (bevacizumab-vikg; bevacizumab gamma), for the treatment of retina diseases, today announced that it will present at the Virtual Investor Pitch Conference on June 18, 2024 at 12:00 PM ET.
Fri, 06 Sep 2024 01:45:00 GMT Capricor management will present updates on Capricor's recent progress on its ... Cautionary Note Regarding Forward-Looking Statements Statements in this press release regarding the efficacy, safety, ...
Wed, 04 Sep 2024 13:30:00 GMT REDWOOD CITY, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to ...
Wed, 04 Sep 2024 05:41:00 GMT NORSE EIGHT is a randomized, controlled, parallel-group, masked, non-inferiority study of newly diagnosed, wet AMD subjects randomized in a 1:1 ratio to receive 1.25 mg ONS-5010 or 0.5 mg ranibizumab ...
Tue, 03 Sep 2024 05:19:00 GMT NKGen is a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic, and CAR-NK NK cell therapeutics. NKGen is headquartered in Santa ...
Fri, 30 Aug 2024 05:00:00 GMT Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by allergic and immunologic diseases. Our lead program ...
